Introduction

35
Clostridium botulinum is a Gram-positive, spore-forming anaerobic bacterium that produces 36 botulinum neurotoxin, which is the most poisonous biological substance known to mankind. 37 Botulinum neurotoxin blocks neurotransmission in cholinergic nerves (1, 2) in humans and 38 animals to cause botulism, a potentially lethal flaccid paralysis. Despite its extreme toxicity, 39 botulinum neurotoxin is widely utilized as a powerful therapeutic agent to treat numerous 40 neurological disorders (3, 4). 41 Seven antigenically distinct botulinum neurotoxin types (A to G), and several subtypes 42 therein, have been identified (5-9). Moreover, a novel toxin type H was recently proposed 43 (10) and awaits further characterization (11). Type A1 neurotoxin is well-characterized as a 44 consequence both of its frequent involvement in human botulism worldwide and of its use 45 as a therapeutic agent (12). Type A1 neurotoxin is produced as a complex containing the 46 neurotoxin itself and associated non-toxic proteins (ANTPs) that comprise a non-toxic non- 47 hemagglutinin protein (NTNH) and three hemagglutinin proteins (HAs; HA17, HA33 and 48 HA70) (13-15). The NTNH protects the neurotoxin from low pH-and protease-induced 49 inactivation in gastrointestinal tract (16), while the HAs assist the neurotoxin absorption, 50 probably by interacting with oligosaccharides and E-cadherin on intestinal epithelial cells 51 (17). 52 In C. botulinum type A1, the genes encoding the neurotoxin (botA) and ANTPs (ntnh, 
Materials and methods
90
Strains, plasmids, oligonucleotides, and culture. Bacterial strains and plasmids used in this 91 study are listed in Table S1 , and all oligonucleotide primers in Tris-HCl, pH 7.9). The bound protein was removed with 4 ml of elution buffer (500 mM NaCl, 173 500 mM imidazole, 20 mM Tris-HCl, pH 7.9). Eluted proteins were examined by SDS-PAGE 174 prior to dialysis using Novagen D-tube TM Dialyzer against 500 ml of dialysis buffer (300 mM Southern blot analysis with a probe specific for the Ll.LtrB-derived intron (Fig. 1B) .
211
Expression of CodY was analyzed using Western blotting with antibodies raised against B.
212
subtilis CodY (32). In contrast to WT, the mutant failed to express CodY (Fig. 1C) . Finally, a 213 slightly lower optical density (OD 600 ) was observed for the codY mutant than for WT at the 214 transition between late exponential and early stationary growth phases (Fig. S1 ). However, phases (9 h) in both strains (Fig. 2) , suggesting that the tightly regulated neurotoxin the codY mutant were half of those observed in the WT, with most prominent differences 225 being observed at 9 h of growth (Fig. 2) .
226
To investigate whether the neurotoxin production is affected by the codY mutation, and late stationary growth phases (Fig. 3) . In the WT culture supernatant, the neurotoxin 231 concentrations peaked at 60 μg/ml at 48 h of growth, whereas the toxin concentrations in (Fig. 4) . Expectedly, the neurotoxin concentration in the culture supernatant of WT-253 pMTL82151::codY was also significantly higher than that in the WT-pMTL82151 supernatant 254 (Fig. 5) .
255
Taken together, these data suggest that CodY plays a positive regulatory role in 256 transcription of the botulinum neurotoxin gene cluster and neurotoxin production. present, an enhanced binding affinity of CodY was observed with Pntnh-botA probe (Fig. 6B) .
269
In contrast, the presence of 10 mM BCAAs did not enhance the binding affinity of CodY to 270 Pntnh-botA probe (Fig. 6C) . A 16S rrn fragment (P16S rrn probe), serving as a negative 271 control, did not show a significant shift with increased concentration of CodY (Fig. 6D) . 
308
The AT count of the Pntnh-botA probe is higher than 75%, which facilitates the presence of 
